Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Swine Flu Vaccines Likely to Be Shielded From Tort Claims

Executive Summary

Vaccine manufacturers are ready to begin producing swine flu vaccines once the government gives them the nod to go forward. As they do so, they may be free from one worry: the risk of being sued for vaccine-related injuries

You may also be interested in...



As WHO Declares Swine Flu Pandemic, Vaccine Makers Could Soon Be Wallowing In Profits

HONG KONG - Demand is likely to increase for an A/H1N1 vaccine following a decision by the World Health Organization to declare a pandemic, even if the alert upgrade is unlikely to do much to speed up production already underway

Poised To Produce A/H1N1 Vaccine, Sanofi Pasteur Ramping Up Capacity In U.S., Developing Defense For Another Killer Virus

BEIJING - On standby to rapidly turn out a vaccine for A/H1N1 if the World Health Organization declares a continents-wide pandemic is emerging, scientists at Sanofi Pasteur are also working with the UN group to develop a defense for the tropical dengue virus, which has already killed far more people worldwide than the swine flu

Vaccine Makers Ask Supreme Court To Assess Their Liability In Tort Claims

The U.S. Supreme Court is once again being asked to consider when personal injury suits are pre-empted by federal law. This time the focus is on vaccine-related injuries

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel